Press release
Bone Therapeutics to participate in upcoming key investor and partnering conferences in Q4 2017
Gosselies, Belgium, 24 October 2017, 7am CEST - BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that it will participate in the following upcoming key investor and partnering conferences in the fourth quarter of 2017:
Bio-Europe
Date: 6-8 November 2017
Venue: Berlin, Germany
Jefferies 2017 London Healthcare Conference
Date: 15-16 November 2017
Venue: London, UK
Third National Congress on Regenerative Medicine
Date: 15-18 November 2017
Venue: Moscow, Russia
Bryan, Garnier & Co 5th Annual Healthcare Conference
Date: 16-17 November 2017
Venue: Paris, France
Invest Securities BioMed Event ®
Date: 19 December 2017
Venue: Paris, France
Bone Therapeutics will also welcome private investors at the following retail events:
Finance Avenue
Date: 18 November 2017
Venue: Brussels, Belgium
Salon Actionaria
Date: 23-24 November 2017
Venue: Paris, France
About Bone Therapeutics
Bone Therapeutics is a leading cell therapy company addressing high unmet needs in orthopaedics and bone diseases. Based in Gosselies, Belgium, the Company has a broad, diversified portfolio of bone cell therapy products in clinical development across a number of disease areas targeting markets with large unmet medical needs and limited innovation.
Our technology is based on a unique, proprietary approach to bone regeneration which turns undifferentiated stem cells into "osteoblastic", or bone-forming cells. These cells can be administered via a minimally invasive procedure, avoiding the need for invasive surgery.
Our primary clinical focus is ALLOB®, an allogeneic "off-the-shelf" cell therapy product derived from stem cells of healthy donors, which is in Phase II studies for the treatment of delayed-union fractures and spinal fusion. The Company also has an autologous bone cell therapy product, PREOB®, obtained from patient`s own bone marrow and currently in Phase III development for osteonecrosis.
Bone Therapeutics` cell therapy products are manufactured to the highest GMP standards and are protected by a rich IP estate covering nine patent families. Further information is available at: www.bonetherapeutics.com.
Contacts
Bone Therapeutics SA
Thomas Lienard, Chief Executive Officer
Jean-Luc Vandebroek, Chief Financial Officer
Tel: +32 (0)2 529 59 90
investorrelations@bonetherapeutics.com
For Belgium and International Media Enquiries:
Consilium Strategic Communications
Amber Fennell, Jessica Hodgson and Hendrik Thys
Tel: +44 (0) 20 3709 5701
bonetherapeutics@consilium-comms.com